Olympian Clinical Research

MARCH 1, 2024

If you are wondering how to remove age spots, Academic Alliance in Dermatology can help. Genetics, hormonal changes, and certain medications can also play a role in developing age spots. Our team of experienced dermatology providers can help you determine the most suitable treatment plan tailored to your specific needs.

Dermatology 52

Dermatology Production Cosmetics Hormones 52

XTalks

MARCH 6, 2023

The portfolio contains approximately forty-five commercial products, four products in the pipeline, and forty approved non-marketed products, many of which are generics focused on women’s health. Some of the higher-value approved products include contraceptives, such as hormonal vaginal rings and birth control pills.

Production 82

Production Branding Dermatology Hormones 82

The Pharma Data

AUGUST 17, 2021

Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Initiate hormone replacement as clinically indicated.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

JULY 23, 2021

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Hormones 52

Hormones Trials Genomics Genome 52

The Pharma Data

MARCH 11, 2021

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Trials 52

Trials Hormones Genomics Genome 52

The Pharma Data

AUGUST 11, 2020

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

OPDIVO ® (nivolumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52